These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

143 related items for PubMed ID: 18059481

  • 1. Subcellular distribution of p210(BCR-ABL) in CML cell lines and primary CD34+ CML cells.
    Patel H, Marley SB, Greener L, Gordon MY.
    Leukemia; 2008 Mar; 22(3):559-71. PubMed ID: 18059481
    [Abstract] [Full Text] [Related]

  • 2. Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies.
    Jiang X, Zhao Y, Smith C, Gasparetto M, Turhan A, Eaves A, Eaves C.
    Leukemia; 2007 May; 21(5):926-35. PubMed ID: 17330101
    [Abstract] [Full Text] [Related]

  • 3. Apoptosis in chronic myeloid leukemia cells transiently treated with imatinib or dasatinib is caused by residual BCR-ABL kinase inhibition.
    Simara P, Stejskal S, Koutna I, Potesil D, Tesarova L, Potesilova M, Zdrahal Z, Mayer J.
    Am J Hematol; 2013 May; 88(5):385-93. PubMed ID: 23420553
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Phosphorylation levels of BCR-ABL, CrkL, AKT and STAT5 in imatinib-resistant chronic myeloid leukemia cells implicate alternative pathway usage as a survival strategy.
    Jilani I, Kantarjian H, Gorre M, Cortes J, Ottmann O, Bhalla K, Giles FJ, Albitar M.
    Leuk Res; 2008 Apr; 32(4):643-9. PubMed ID: 17900686
    [Abstract] [Full Text] [Related]

  • 6. [Clinical significance of CRKL protein phosphorylation level in the treatment of chronic myeloid leukemia with imatinib].
    Xu N, Ouyang Z, DU QF, Wang S, Yang J, Wang Y, Liu XL.
    Zhonghua Xue Ye Xue Za Zhi; 2011 Jan; 32(1):25-8. PubMed ID: 21429397
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. PHA-680626 exhibits anti-proliferative and pro-apoptotic activity on Imatinib-resistant chronic myeloid leukemia cell lines and primary CD34+ cells by inhibition of both Bcr-Abl tyrosine kinase and Aurora kinases.
    Gontarewicz A, Balabanov S, Keller G, Panse J, Schafhausen P, Bokemeyer C, Fiedler W, Moll J, Brümmendorf TH.
    Leuk Res; 2008 Dec; 32(12):1857-65. PubMed ID: 18514829
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Characterization of p87C3G, a novel, truncated C3G isoform that is overexpressed in chronic myeloid leukemia and interacts with Bcr-Abl.
    Gutiérrez-Berzal J, Castellano E, Martín-Encabo S, Gutiérrez-Cianca N, Hernández JM, Santos E, Guerrero C.
    Exp Cell Res; 2006 Apr 01; 312(6):938-48. PubMed ID: 16443220
    [Abstract] [Full Text] [Related]

  • 11. A novel FRET-based biosensor for the measurement of BCR-ABL activity and its response to drugs in living cells.
    Mizutani T, Kondo T, Darmanin S, Tsuda M, Tanaka S, Tobiume M, Asaka M, Ohba Y.
    Clin Cancer Res; 2010 Aug 01; 16(15):3964-75. PubMed ID: 20670950
    [Abstract] [Full Text] [Related]

  • 12. p210(Bcr-Abl) desensitizes Cdc42 GTPase signaling for SDF-1alpha-directed migration in chronic myeloid leukemia cells.
    Chang YC, Tien SC, Tien HF, Zhang H, Bokoch GM, Chang ZF.
    Oncogene; 2009 Nov 19; 28(46):4105-15. PubMed ID: 19718053
    [Abstract] [Full Text] [Related]

  • 13. Inhibition of Grb2 and Crkl proteins results in growth inhibition of Philadelphia chromosome positive leukemic cells.
    Tari AM, Arlinghaus R, Lopez-Berestein G.
    Biochem Biophys Res Commun; 1997 Jun 18; 235(2):383-8. PubMed ID: 9199202
    [Abstract] [Full Text] [Related]

  • 14. Cathepsin B release after imatinib-mediated lysosomal membrane permeabilization triggers BCR-ABL cleavage and elimination of chronic myelogenous leukemia cells.
    Puissant A, Colosetti P, Robert G, Cassuto JP, Raynaud S, Auberger P.
    Leukemia; 2010 Jan 18; 24(1):115-24. PubMed ID: 19924144
    [Abstract] [Full Text] [Related]

  • 15. Different target range and cytotoxic specificity of adaphostin and 17-allylamino-17-demethoxygeldanamycin in imatinib-resistant and sensitive cell lines.
    Barnes DJ, De S, van Hensbergen P, Moravcsik E, Melo JV.
    Leukemia; 2007 Mar 18; 21(3):421-6. PubMed ID: 17252018
    [Abstract] [Full Text] [Related]

  • 16. Cellular interactions of CRKL, and SH2-SH3 adaptor protein.
    ten Hoeve J, Kaartinen V, Fioretos T, Haataja L, Voncken JW, Heisterkamp N, Groffen J.
    Cancer Res; 1994 May 15; 54(10):2563-7. PubMed ID: 8168080
    [Abstract] [Full Text] [Related]

  • 17. BCR-ABL induces the expression of Skp2 through the PI3K pathway to promote p27Kip1 degradation and proliferation of chronic myelogenous leukemia cells.
    Andreu EJ, Lledó E, Poch E, Ivorra C, Albero MP, Martínez-Climent JA, Montiel-Duarte C, Rifón J, Pérez-Calvo J, Arbona C, Prósper F, Pérez-Roger I.
    Cancer Res; 2005 Apr 15; 65(8):3264-72. PubMed ID: 15833859
    [Abstract] [Full Text] [Related]

  • 18. Rapid detection of phosphotyrosine proteins by flow cytometric analysis in Bcr-Abl-positive cells.
    Desplat V, Lagarde V, Belloc F, Chollet C, Leguay T, Pasquet JM, Praloran V, Mahon FX.
    Cytometry A; 2004 Nov 15; 62(1):35-45. PubMed ID: 15468123
    [Abstract] [Full Text] [Related]

  • 19. BCR-ABL activity and its response to drugs can be determined in CD34+ CML stem cells by CrkL phosphorylation status using flow cytometry.
    Hamilton A, Elrick L, Myssina S, Copland M, Jørgensen H, Melo JV, Holyoake T.
    Leukemia; 2006 Jun 15; 20(6):1035-9. PubMed ID: 16572205
    [Abstract] [Full Text] [Related]

  • 20. Measurement of in vivo BCR-ABL kinase inhibition to monitor imatinib-induced target blockade and predict response in chronic myeloid leukemia.
    White D, Saunders V, Grigg A, Arthur C, Filshie R, Leahy MF, Lynch K, To LB, Hughes T.
    J Clin Oncol; 2007 Oct 01; 25(28):4445-51. PubMed ID: 17906206
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.